PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 48 filers reported holding PHATHOM PHARMACEUTICALS INC in Q1 2020. The put-call ratio across all filers is - and the average weighting 2.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $60 | -25.9% | 5,825 | +2.8% | 0.00% | – |
| Q2 2023 | $81 | -22.1% | 5,666 | -61.2% | 0.00% | – |
| Q1 2023 | $104 | -36.6% | 14,603 | 0.0% | 0.00% | – |
| Q4 2022 | $164 | -99.9% | 14,603 | -0.6% | 0.00% | – |
| Q3 2022 | $163,000 | +32.5% | 14,686 | +1.0% | 0.00% | – |
| Q2 2022 | $123,000 | -37.9% | 14,536 | -0.2% | 0.00% | – |
| Q1 2022 | $198,000 | -31.0% | 14,569 | 0.0% | 0.00% | – |
| Q4 2021 | $287,000 | -38.8% | 14,569 | -0.3% | 0.00% | – |
| Q3 2021 | $469,000 | -20.8% | 14,617 | -16.5% | 0.00% | -100.0% |
| Q2 2021 | $592,000 | +62.6% | 17,495 | +80.4% | 0.00% | – |
| Q1 2021 | $364,000 | +13.0% | 9,700 | 0.0% | 0.00% | – |
| Q4 2020 | $322,000 | -9.6% | 9,700 | 0.0% | 0.00% | – |
| Q3 2020 | $356,000 | +11.6% | 9,700 | 0.0% | 0.00% | – |
| Q2 2020 | $319,000 | +27.6% | 9,700 | 0.0% | 0.00% | – |
| Q1 2020 | $250,000 | -17.2% | 9,700 | 0.0% | 0.00% | – |
| Q4 2019 | $302,000 | – | 9,700 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 2,067,861 | $68,694,000 | 39.92% |
| Greenspring Associates, LLC | 360,939 | $11,990,000 | 15.57% |
| FRAZIER MANAGEMENT LLC | 5,827,415 | $193,587,000 | 14.91% |
| Abingworth LLP | 1,203,135 | $39,956,000 | 13.67% |
| Penn Mutual Asset Management | 86,940 | $2,888,000 | 2.55% |
| RA Capital Management | 3,825,008 | $127,067,000 | 1.78% |
| LUMINUS MANAGEMENT LLC | 126,903 | $4,216,000 | 0.98% |
| Pinz Capital Management, LP | 33,600 | $1,116,000 | 0.51% |
| Rhenman & Partners Asset Management AB | 175,000 | $5,814,000 | 0.47% |
| Summit Rock Advisors, LP | 34,350 | $1,141,000 | 0.40% |